“showed a trend”

Baseline pain level showed a trend toward a negative impact on health outcomes (Coef. = −0.4896, p = 0.0579).

RA patients showed a trend towards decreased CD126 + lymphocytes (mean [ s . d .] 52 [11]%; median 55 [27–81]%; Mann–Whitney P = 0.0579) compared with healthy individuals, but higher ( P = 0.0149) than SLE patients.

Macrophages from WT mice fed dietary PUFAs (FO, EO, and BO) had significantly decreased or showed a trend toward decease in mRNA expression of IL-1β (FO; P = 0.0579) and NLRP3.

Similarly, CD133 showed a trend toward lower expression in 2D cultures compared to PDOs ( p = .0579).

Of note, no homotopic pairs of regions differed from one another in terms of modulation by linguistic demand or the interaction of domain by difficulty, though the anterior insula showed a trend toward an interaction, with less of a discrepancy between domains in the left anterior insula compared to the right ( p = 0.058).

Severely affected patients had lower VH than moderately affected patients (−28.86%, p = 0.045), while the difference between the severe and mild groups only showed a trend (−23.56%, p = 0.058) (see Figure 3 ). 3.2.

Furthermore, rheumatoid arthritis showed a trend towards correlation with overweight and obese 3 (aOR 7.6 and 10.3, p=0.058 and 0.056, respectively).

The reciprocal deletion in this region showed a trend toward a negative effect on cognitive ability (z = −0.526, SD = 0.276, p = 0.058), but we were underpowered with only 12 carriers.

Development of immune-related adverse events (irAE; e.g., hypothyroidism or vitiligo) within 6 months showed a trend toward better OS in multivariable analysis (HR, 0.37; p=.058).

In a multivariate analysis, an LAD-LCX angle greater than 60° showed a trend toward predicting significant LAD stenosis (HR, 3.14; 95% CI: 0.96–1026; P = 0.058).

OS in the high SMI group showed a trend toward being higher than that in the low SMI group ( P = .058) (Fig. 4 ).

KPS <70 showed a trend (HR 1.44 [0.99–2.1], p = 0.058) towards deteriorated OS.

At the same time, however, electron transport rates at in situ light (isETR) showed a trend for lower values with increasing temperature (lme: P = 0.058; fig.

The proportion of ITGB7 + IgA2 early PBs showed a trend toward reduction ( p = 0.058) ( Figures 4 D and 4E), while the proportion of ITGB1-expressing early PBs trended upward ( p = 0.073) ( Figure 4 D) after belimumab-rituximab combination therapy compared to after rituximab alone (where the proportion of ITGB7 + IgA2 early PBs increased).

As reported in Table 3 , although a less than acceptable discriminatory power persisted for this miRNAs panel, the combination of the three miRNAs with the CA 19-9 determinations (jointly considered) showed a trend toward a better discriminatory ability (AUC = 0.936; 95%CI: 0.904-0.968) compared to the CA 19-9 test alone ( p = 0.058 from DeLong test).

Distance traveled in the OF showed a trend for an effect of subgroups [LMM, F (1,64) = 3.971, η 2 p = 0.058, p = 0.051], with mice from the continuation subgroups traveling slightly more than mice from the termination subgroups.

Nonmusicians differed significantly from guitarists, t (38) = 3.7, P = 0.001, and showed a trend for a difference from beatboxers, t (38) = 2.0, P = 0.058.

Restricting the analyses to participants without risky alcohol consumption (< 8 on AUDIT) (patients = 103, 48% men, mean age = 40.9 years; controls = 46, 50% men, mean age 40.5 years) showed a trend to lower DHEA-s levels in the patient group than in controls (p = 0.058), but otherwise the same results, thus, lower DHEA-s in patients only in the youngest age-group when analyzing age groups separately (data not shown).

CA19-9 level subgroup: In patients with CA19-9 ≥700 U/mL (experimental group, n = 8; control group, n = 7), the experimental group showed a trend toward longer median OS (22.3 months vs. 15.7 months, log-rank P = 0.058).

Moreover, patients with concurrent high HSP27 and low PTEN expression also showed a trend toward worse outcomes (log-rank test p = 0.058).

However, after PSM, carvedilol at doses >25 mg/day significantly reduced 30-day (HR = 0.50 95%CI: 0.30, 0.85, p = 0.011) and 360-day all-cause mortality (HR = 0.68 95%CI: 0.49, 0.94, p = 0.020) and showed a trend toward reducing 7-day all-cause mortality (HR = 0.46 95%CI: 0.20, 1.03, p = 0.058), though without statistical significance.

The association between age and PAI-1 showed a trend for significance ( P =0.058).

The results showed a trend whereby the infants that looked more to target words at utterance-edge position than to unfamiliar words [ r (32) = 0.33, p = 0.058] and that looked more at target words at utterance-medial position than to unfamiliar words [ r (32) = 0.33, p = 0.052] have larger later expressive vocabulary outcomes measured with the CDI percentile.

Patients with an above-median baseline 89 ZED88082A-uptake geometric mean SUV max (that is, >5.2) showed a trend towards superior progression-free survival (PFS) (median 1.5, 95% CI 1.3 to not reached; versus 3.9, 95% CI 2.6 to not reached, P = 0.058) and had superior overall survival (OS) to patients with an uptake below the median (median 6.5, 95% CI 3.3 to not reached, versus 13.8, 95% CI 11.3 to not reached, P = 0.030) (Fig. 4 ).

In a sub-analysis restricted to paroxysmal AF patients, pre-procedural time spent in AF showed a trend toward an association with AF recurrence (HR 1.08 per 10% increase, 95% CI 1.00–1.18, P = 0.058); this model was adjusted for age, sex, chronic obstructive pulmonary disease, diabetes mellitus, and thyroid dysfunction (see Supplementary material online , Table S3 ).